Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Home
<
List for "R03DX" (22)
–
Sort according to Concentration, Size and Price
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
Omalizumab (R03DX05) 12 products
WHO-DDD
DrugBank.ca
L
IP
CI
Xolair 75 mg/0.5 ml
166.63
194.90
10 %
Injection solution in prefilled syringe: Omalizumabum 75mg / 0.5ml
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
CI
Xolair 75 mg/0.5 ml
166.63
194.90
10 %
Injection solution in prefilled syringe: Omalizumabum 75mg / 0.5ml
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
CI
Xolair 150 mg/1.0 ml
333.25
373.35
10 %
Injection solution in prefilled syringe: Omalizumabum 150mg / 1ml
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
CI
Xolair 150 mg/1.0 ml
333.25
373.35
10 %
Injection solution in prefilled syringe: Omalizumabum 150mg / 1ml
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
CI
Xolair 300 mg/2 ml
666.50
741.25
10 %
Injection solution in prefilled syringe: Omalizumabum 300mg / 2ml
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
SIP
IP
CI
Xolair 150 mg
ampoule(s)
333.25
373.35
10 %
Lyophilisate and solvent: Omalizumabum 150 mg
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
CI
Xolair 150 mg/1.0 ml
333.25
373.35
10 %
Injektionslösung in einem Fertigpen: Omalizumabum 150 mg/ml
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
CI
Xolair 300 mg/2.0 ml
666.50
741.25
10 %
Injektionslösung in einem Fertigpen: Omalizumabum 300mg / 2ml
Novartis Pharma
Schweiz AG
B / SL
FB
G
L
IP
CI
Omlyclo 75 mg/0.5 ml
122.15
149.25
10 %
solution injectable en seringue préremplie: Omalizumabum 75mg / 0.5ml
iQone Healthcare
Switzerland SA
B / SL
FB
G
L
IP
CI
Omlyclo 150 mg/1 ml
244.29
282.10
10 %
solution injectable en seringue préremplie: Omalizumabum 150 mg/ml
iQone Healthcare
Switzerland SA
B / SL
FB
G
SIP
IP
CI
Xolair 75 mg
ampoule(s)
k.A.
Lyophilisate and solvent: Omalizumabum 75 mg
Novartis Pharma
Schweiz AG
B
FB
G
IP
CI
Xolair 75 mg/0.5 ml
k.A.
Injektionslösung in einem Fertigpen: Omalizumabum 75mg / 0.5ml
Novartis Pharma
Schweiz AG
B
FB
G
Roflumilast (R03DX07) 2 products
WHO-DDD
DrugBank.ca
IP
CI
Daxas 500 ug
30 Tablet(s)
54.06
75.20
10 %
Coated tablets: Roflumilastum 500 µg
AstraZeneca AG
B / SL
FB
G
IP
CI
Daxas 500 ug
90 Tablet(s)
137.85
166.35
10 %
Coated tablets: Roflumilastum 500 µg
AstraZeneca AG
B / SL
FB
G
Reslizumab (R03DX08) 2 products
WHO-DDD
L
IP
Cinqaero 100 mg/10 mL
510.32
571.40
10 %
Concentrate for infusion: Reslizumabum 100mg / 10ml
Teva Pharma AG
B / SL
FB
G
L
IP
Cinqaero 25 mg/2,5 mL
127.59
155.20
10 %
Concentrate for infusion: Reslizumabum 25mg / 2.5ml
Teva Pharma AG
B / SL
FB
G
Mepolizumab (R03DX09) 2 products
WHO-DDD
L
IP
CI
Nucala 100 mg/mL
976.63
1078.55
10 %
Injektionslösung im Fertigpen: Mepolizumabum 100mg / 1ml
GlaxoSmithKline AG
B / SL
FB
G
L
IP
CI
Nucala 100 mg/mL
976.63
1078.55
10 %
Injektionslösung in der Fertigspritze: Mepolizumabum 100mg / 1ml
GlaxoSmithKline AG
B / SL
FB
G
Benralizumab (R03DX10) 2 products
WHO-DDD
L
IP
CI
Fasenra 30 mg /1 ml
1929.05
2114.35
10 %
Injection solution in prefilled syringe: Benralizumabum 30 mg/ml
AstraZeneca AG
B / SL
FB
G
L
IP
CI
Fasenra Pen 30 mg /1 ml
1929.05
2114.35
10 %
lnjektionslösung: Benralizumabum 30 mg/ml
AstraZeneca AG
B / SL
FB
G
Tezepelumab (R03DX11) 2 products
WHO-DDD
L
IP
CI
Tezspire
1036.42
1143.60
10 %
Injection solution in prefilled syringe: Tezepelumabum 210 mg
AstraZeneca AG
B / SL
FB
G
L
IP
CI
Tezspire 110 mg/ml
1036.42
1143.60
10 %
Injektionslösung in einem Fertigpen: Tezepelumabum 210 mg
AstraZeneca AG
B / SL
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2026
©ywesee GmbH
Settings
|
Help
|
Login
|
Contact
|
Home